RecruitingPhase 2NCT03764098

Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders

Sponsor

Yale University

Enrollment

160 participants

Start Date

Aug 10, 2020

Study Type

INTERVENTIONAL

Conditions

Alcohol Use

Summary

For this protocol, the investigators plan to collect pilot data to examine sex differences in guanfacine's effect on 1) counteracting stress and stimulation based drinking behavior in the laboratory and 2) improving clinical outcomes during a subsequent treatment phase.

Eligibility

Min Age: 21 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Guanfacine ER and Placebo for people with alcohol use. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGuanfacine ER

Guanfacine Extended Release (6mg/day ER)

OTHERPlacebo

Placebo

Locations(1)

Yale University School of Medicine

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03764098

Related Trials

Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment

NCT073425041 location

Multi-Component Breath Alcohol Intervention Phase 3

NCT069949621 location